Cardiac Imaging: Page 2

Philips gets FDA nod for Cardiovascular Workspace
By AuntMinnie.com staff writers
Philips has received U.S. Food and Drug Administration (FDA) clearance for the latest release of Cardiovascular Workspace.
November 14, 2025
Heart 400 (1)
Esaote enters partnership with Schiller Americas
By AuntMinnie.com staff writers
Esaote North America has entered into a partnership with Schiller Americas for the distribution of its MyLab ultrasound systems.
November 13, 2025
MyLab E80
Elucid launches CT-based plaque analysis software
By AuntMinnie.com staff writers
Firm highlights lipid-rich necrotic core, a vulnerable component of noncalcified plaque.
October 31, 2025
Plaque Artery 6 Wie8o8kz T
Cardiac POCUS training leads to success for neonatal transport teams
By Amerigo Allegretto
Training leads to successful image acquisition and congenital heart disease diagnosis in infants for transport team members.
October 20, 2025
2025 10 18 Airmj Shutes Pocus Transport Team Thumbnail
Abnormal CT-FFR results translate to up to 7 years of cardiovascular risk
By Kate Madden Yee
The prognostic value of CT fractional flow reserve (CT-FFR) has been unclear, but a recent study's findings offer further insight.
October 14, 2025
Heart Damage
ICE noninferior to TEE for atrial fibrillation ablation safety
By Amerigo Allegretto
Intracardiac echocardiography (ICE) is comparable to transesophageal echocardiography (TEE) for atrial fibrillation ablation procedures.
October 8, 2025
Heart Ultrasound Adobe Peakstock
ASTRO: STAR has role in managing VT in cardiac patients
By Amerigo Allegretto
Stereotactic arrhythmia radiotherapy (STAR) is safe and effective for treating refractory VT compared to repeat catheter ablation.
October 1, 2025
Img 2757
Biograph and Caristo advance coronary inflammation study in U.S.
By AuntMinnie.com staff writers
The research will evaluate whether coronary inflammation alongside plaque characterization can detect early heart disease.
October 1, 2025
Heart Glowing Red
Cleerly highlights coverage decision effective October 1
By AuntMinnie.com staff writers
Cleerly's AI-QCT software for cardiovascular imaging will be eligible for reimbursement from UnitedHealthcare and Cigna on October 1.
September 30, 2025
Insurance Claim Reimbursement Vinnstock
HeartFlow secures 510(k) for next-gen algorithm
By AuntMinnie.com staff writers
Corresponding with the FDA clearance, the company also highlighted the unveiling of its DECIDE Registry.
September 23, 2025
Heart Glowing Red
Tempus AI secures 510(k) for Pixel
By AuntMinnie.com staff writers
The update reflects new software functionality designed for a comprehensive view of heart tissue.
September 12, 2025
Cardiac Heart Eeg Social (1)
Low-dose CT ties emphysema to mortality in previous smokers
By Amerigo Allegretto
Study findings highlight the clinical relevance of CT-diagnosed emphysema.
September 9, 2025
Representative axial images of mild, moderate, and severe emphysema at baseline low-dose CT (LDCT). Participants were categorized as having no emphysema or mild, moderate, or severe emphysema. When present, emphysema was mild if no distinct regions of reduced attenuation were visible on the CT scan, but vascular splaying indicates parenchymal expansion, or if only occasional discrete low-attenuation regions were observed. Moderate emphysema was defined by the presence of identifiable low-attenuation regions affecting less than half of the lung parenchyma, whereas severe emphysema was defined by the presence of identifiable low-attenuation regions that involved more than half of the lung parenchyma. A scoring system from 0 to 3 was applied, corresponding to none, mild, moderate, and severe emphysema, respectively. Yellow circle indicates the extent of emphysema. (A) A 67-year-old man with mild emphysema at baseline LDCT in 2002. Baseline LDCT scan shows vascular splaying, suggesting parenchymal expansion due to emphysema and occasional discrete low-attenuation regions. The participant ultimately died of cardiovascular disease 15.4 years (184.2 months) later. (B) A 69-year-old man with moderate emphysema at baseline LDCT in 2007. The participant died of cardiovascular disease 1.8 years (21.9 months) later. Identifiable low-attenuation regions affected less than half of the lung parenchyma. (C) An 85-year-old woman with severe emphysema at baseline LDCT in 2006. After 5.5 years (65.5 months) of follow-up, the participant died due to chronic obstructive pulmonary disease–related causes. Identifiable low-attenuation regions involved more than half of the lung parenchyma.
Previous Page
Page 2 of 325
Next Page